Stay updated with breaking news from Pacifica Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.
Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.